JP2013541339A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013541339A5 JP2013541339A5 JP2013532235A JP2013532235A JP2013541339A5 JP 2013541339 A5 JP2013541339 A5 JP 2013541339A5 JP 2013532235 A JP2013532235 A JP 2013532235A JP 2013532235 A JP2013532235 A JP 2013532235A JP 2013541339 A5 JP2013541339 A5 JP 2013541339A5
- Authority
- JP
- Japan
- Prior art keywords
- expression level
- maf
- gene
- metastasis
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 44
- 102100039189 Transcription factor Maf Human genes 0.000 claims description 41
- 230000014509 gene expression Effects 0.000 claims description 39
- 206010027476 Metastases Diseases 0.000 claims description 37
- 230000009401 metastasis Effects 0.000 claims description 36
- 108090000623 proteins and genes Proteins 0.000 claims description 34
- 206010006187 Breast cancer Diseases 0.000 claims description 18
- 208000026310 Breast neoplasm Diseases 0.000 claims description 18
- 239000013068 control sample Substances 0.000 claims description 17
- 102000014128 RANK Ligand Human genes 0.000 claims description 16
- 108010025832 RANK Ligand Proteins 0.000 claims description 16
- 210000000988 bone and bone Anatomy 0.000 claims description 16
- 239000000523 sample Substances 0.000 claims description 14
- 210000001519 tissue Anatomy 0.000 claims description 13
- 239000003112 inhibitor Substances 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 230000003321 amplification Effects 0.000 claims description 9
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 9
- 229940122361 Bisphosphonate Drugs 0.000 claims description 8
- 150000004663 bisphosphonates Chemical class 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 7
- 108020004635 Complementary DNA Proteins 0.000 claims description 6
- 206010027452 Metastases to bone Diseases 0.000 claims description 6
- 238000010804 cDNA synthesis Methods 0.000 claims description 6
- 239000002299 complementary DNA Substances 0.000 claims description 6
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 108020004999 messenger RNA Proteins 0.000 claims description 6
- 230000015556 catabolic process Effects 0.000 claims description 5
- 238000006731 degradation reaction Methods 0.000 claims description 5
- 230000000010 osteolytic effect Effects 0.000 claims description 5
- 102000055006 Calcitonin Human genes 0.000 claims description 4
- 108060001064 Calcitonin Proteins 0.000 claims description 4
- 102000004171 Cathepsin K Human genes 0.000 claims description 4
- 108090000625 Cathepsin K Proteins 0.000 claims description 4
- 208000003076 Osteolysis Diseases 0.000 claims description 4
- 102000008108 Osteoprotegerin Human genes 0.000 claims description 4
- 108010035042 Osteoprotegerin Proteins 0.000 claims description 4
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 4
- 229960004015 calcitonin Drugs 0.000 claims description 4
- 229960001251 denosumab Drugs 0.000 claims description 4
- 239000002834 estrogen receptor modulator Substances 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 208000029791 lytic metastatic bone lesion Diseases 0.000 claims description 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 4
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 claims description 4
- 238000003752 polymerase chain reaction Methods 0.000 claims description 4
- 238000004393 prognosis Methods 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 229940079488 strontium ranelate Drugs 0.000 claims description 4
- XXUZFRDUEGQHOV-UHFFFAOYSA-J strontium ranelate Chemical compound [Sr+2].[Sr+2].[O-]C(=O)CN(CC([O-])=O)C=1SC(C([O-])=O)=C(CC([O-])=O)C=1C#N XXUZFRDUEGQHOV-UHFFFAOYSA-J 0.000 claims description 4
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical group OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 4
- 229960004276 zoledronic acid Drugs 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- 102000053642 Catalytic RNA Human genes 0.000 claims description 2
- 108090000994 Catalytic RNA Proteins 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims description 2
- 238000002965 ELISA Methods 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 238000007901 in situ hybridization Methods 0.000 claims description 2
- 238000003498 protein array Methods 0.000 claims description 2
- 238000003753 real-time PCR Methods 0.000 claims description 2
- 108091092562 ribozyme Proteins 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 238000001262 western blot Methods 0.000 claims description 2
- 241000287463 Phalacrocorax Species 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 238000011002 quantification Methods 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201031478A ES2379918B1 (es) | 2010-10-06 | 2010-10-06 | Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama. |
| ESP201031478 | 2010-10-06 | ||
| ESP201131073 | 2011-06-27 | ||
| ES201131073 | 2011-06-27 | ||
| PCT/ES2011/070693 WO2012045905A2 (es) | 2010-10-06 | 2011-10-05 | Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017011967A Division JP6571698B2 (ja) | 2010-10-06 | 2017-01-26 | 乳がん転移の診断、予後診断、および処置のための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013541339A JP2013541339A (ja) | 2013-11-14 |
| JP2013541339A5 true JP2013541339A5 (enExample) | 2014-11-27 |
| JP6159254B2 JP6159254B2 (ja) | 2017-07-12 |
Family
ID=45099129
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013532235A Active JP6159254B2 (ja) | 2010-10-06 | 2011-10-05 | 乳がん転移の診断、予後診断、および処置のための方法 |
| JP2017011967A Active JP6571698B2 (ja) | 2010-10-06 | 2017-01-26 | 乳がん転移の診断、予後診断、および処置のための方法 |
| JP2018054132A Pending JP2018099132A (ja) | 2010-10-06 | 2018-03-22 | 乳がん転移の診断、予後診断、および処置のための方法 |
| JP2019146185A Active JP6946385B2 (ja) | 2010-10-06 | 2019-08-08 | 乳がん転移の診断、予後診断、および処置のための方法 |
| JP2021150170A Pending JP2021192636A (ja) | 2010-10-06 | 2021-09-15 | 乳がん転移の診断、予後診断、および処置のための方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017011967A Active JP6571698B2 (ja) | 2010-10-06 | 2017-01-26 | 乳がん転移の診断、予後診断、および処置のための方法 |
| JP2018054132A Pending JP2018099132A (ja) | 2010-10-06 | 2018-03-22 | 乳がん転移の診断、予後診断、および処置のための方法 |
| JP2019146185A Active JP6946385B2 (ja) | 2010-10-06 | 2019-08-08 | 乳がん転移の診断、予後診断、および処置のための方法 |
| JP2021150170A Pending JP2021192636A (ja) | 2010-10-06 | 2021-09-15 | 乳がん転移の診断、予後診断、および処置のための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10047398B2 (enExample) |
| EP (3) | EP3517630B1 (enExample) |
| JP (5) | JP6159254B2 (enExample) |
| KR (2) | KR102240323B1 (enExample) |
| CN (2) | CN108192972B (enExample) |
| AR (1) | AR083357A1 (enExample) |
| AU (4) | AU2011311452B2 (enExample) |
| BR (1) | BR112013008505B1 (enExample) |
| CA (1) | CA2813674C (enExample) |
| DK (2) | DK3091085T3 (enExample) |
| ES (3) | ES2562274T3 (enExample) |
| MX (2) | MX344315B (enExample) |
| WO (1) | WO2012045905A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2562274T3 (es) | 2010-10-06 | 2016-03-03 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Procedimiento para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de mama |
| EP2650682A1 (en) * | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| ES2705237T3 (es) | 2012-06-06 | 2019-03-22 | Fundacio Inst De Recerca Biomedica Irb Barcelona | Método para el diagnóstico y el pronóstico de metástasis del cáncer de pulmón |
| DK2906718T3 (da) | 2012-10-12 | 2019-07-01 | Inbiomotion Sl | Fremgangsmåde til diagnose, prognose og behandling af prostatakræftmetastase under anvendelse af c-maf |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| US20160032399A1 (en) * | 2013-03-15 | 2016-02-04 | Inbiomotion S.L. | Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis |
| AU2014229505B2 (en) * | 2013-03-15 | 2020-02-27 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the prognosis and treatment of cancer metastasis |
| BR112015023510A2 (pt) * | 2013-03-15 | 2017-10-10 | Fundacio Inst De Recerca Biomedica Irb Barcelona | método para o diagnóstico, prognóstico e tratamento de câncer metastático |
| JP6550045B2 (ja) * | 2013-10-09 | 2019-07-24 | フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）Ｆｕｎｄａｃｉｏ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｒｅｃｅｒｃａ Ｂｉｏｍｅｄｉｃａ （Ｉｒｂ Ｂａｒｃｅｌｏｎａ） | 乳がんに由来する骨の転移がんの予後診断および処置のための方法 |
| EP2933639A1 (en) * | 2014-04-16 | 2015-10-21 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | S100p and Hyaluronic acid as biomarkers for metastatic breast cancer |
| CN104398506A (zh) * | 2014-12-09 | 2015-03-11 | 厦门大学 | 雷奈酸锶在制备预防和治疗腺癌药物中的新用途 |
| JP2017538412A (ja) | 2014-12-11 | 2017-12-28 | インバイオモーション エセ．エレ． | ヒトｃ−ｍａｆに対する結合メンバー |
| CN117230193A (zh) * | 2016-05-25 | 2023-12-15 | 生物运动有限公司 | 基于c-maf状态的乳腺癌治疗性治疗 |
| KR101896558B1 (ko) | 2016-11-21 | 2018-09-07 | 주식회사 젠큐릭스 | 유방암 환자의 예후 예측 방법 |
| CN107699619B (zh) * | 2017-11-17 | 2019-02-22 | 柳超 | lncRNA组合物及制备诊断预示Luminal B型乳腺癌骨转移基因诊断试剂盒的用途 |
| EP3713581A1 (en) | 2017-11-22 | 2020-09-30 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf |
| JP2023079997A (ja) | 2021-11-29 | 2023-06-08 | 東洋インキＳｃホールディングス株式会社 | 活性エネルギー線硬化型インクジェットインキ及び印刷物 |
| CN114574577A (zh) * | 2022-01-04 | 2022-06-03 | 中山大学孙逸仙纪念医院 | Mettl16基因及其用途 |
| CN119614707A (zh) * | 2025-01-13 | 2025-03-14 | 中山大学 | ERα生物标志物在ER+乳腺癌骨转移诊断、治疗和预后中的应用 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0217822B1 (en) | 1985-02-13 | 1993-05-12 | Scios Nova Inc. | Human metallothionein-ii promoter in mammalian expression system |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| DE4013632A1 (de) * | 1990-04-27 | 1991-10-31 | Max Planck Gesellschaft | Liposomen mit positiver ueberschussladung |
| CA2251466A1 (en) | 1996-04-05 | 1997-10-16 | The Salk Institute For Biological Studies | Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| WO1998028424A2 (en) | 1996-12-23 | 1998-07-02 | Immunex Corporation | Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily |
| US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| US6274338B1 (en) | 1998-02-24 | 2001-08-14 | President And Fellows Of Harvard College | Human c-Maf compositions and methods of use thereof |
| HRP20010738B1 (en) | 1999-03-15 | 2005-02-28 | Axys Pharmaceuticals | N-cyanomethyl amides as protease inhibitors |
| US6287813B1 (en) | 1999-04-23 | 2001-09-11 | Cistronics Cell Technology Gmbh | Antibiotic-based gene regulation system |
| DE60132975T2 (de) | 2000-01-06 | 2009-02-26 | Merck Frosst Canada Inc., Kirkland | Neue substanzen und verbindungen als protease-inhibitoren |
| US6750015B2 (en) | 2000-06-28 | 2004-06-15 | Kathryn B. Horwitz | Progesterone receptor-regulated gene expression and methods related thereto |
| ES2706902T3 (es) | 2001-06-26 | 2019-04-01 | Amgen Inc | Anticuerpos para OPGL |
| AR036375A1 (es) | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| GB0121033D0 (en) | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| WO2003043308A2 (en) | 2001-11-13 | 2003-05-22 | Koninklijke Philips Electronics N.V. | Method for calibration and correction of radial lens distortion |
| KR100485271B1 (ko) | 2002-01-16 | 2005-04-27 | 메타볼랩(주) | 전사인자 ｃ－ｍａｆ의 전사 활성 억제제로서의 니발레놀및 그를 포함하는 약제학적 조성물 |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| DE10235624A1 (de) | 2002-08-02 | 2004-02-19 | Aventis Pharma Deutschland Gmbh | Endiandric acid H und ihre Derivate, Verfahren zu ihrer Herstellung und Verwendung derselben |
| US20050181375A1 (en) * | 2003-01-10 | 2005-08-18 | Natasha Aziz | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer |
| WO2005026322A2 (en) | 2003-09-11 | 2005-03-24 | Clontech Laboratories, Inc. | siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME |
| JP4579246B2 (ja) | 2003-09-24 | 2010-11-10 | オンコセラピー・サイエンス株式会社 | 乳癌を診断する方法 |
| WO2005046731A1 (en) | 2003-10-17 | 2005-05-26 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Interference with c-maf function in multiple myeloma |
| WO2005060722A2 (en) | 2003-12-18 | 2005-07-07 | President And Fellows Of Hardvard College | Modulation of immune system function by modulation of polypeptide arginine methyltransferases |
| TW200526224A (en) | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
| EP1730308A4 (en) | 2004-03-05 | 2008-10-08 | Rosetta Inpharmatics Llc | CLASSIFICATION OF BREAST CANCER PATIENTS USING A COMBINATION OF CLINICAL CRITERIA AND INFORMATIVE SKILLS |
| US20080131940A1 (en) | 2004-06-25 | 2008-06-05 | Robert Chiu | Target Cell-Specific Short Interfering Rna and Methods of Use Thereof |
| WO2006135436A2 (en) | 2004-10-22 | 2006-12-21 | University Of Florida Research Foundation, Inc. | Inhibition of gene expression and therapeutic uses thereof |
| US9134237B2 (en) | 2005-09-20 | 2015-09-15 | Janssen Diagnotics, LLC | High sensitivity multiparameter method for rare event analysis in a biological sample |
| EP3211086B1 (en) | 2005-09-20 | 2021-06-09 | Menarini Silicon Biosystems S.p.A. | Methods and composition to generate unique sequence dna probes, labeling of dna probes and the use of these probes |
| EP1931994A2 (en) | 2005-09-26 | 2008-06-18 | Novartis AG | Molecular markers associated with bone metastasis |
| EP1969000A2 (en) | 2005-12-06 | 2008-09-17 | Centre National de la Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| WO2008098351A1 (en) | 2007-02-14 | 2008-08-21 | University Health Network | Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies |
| EP1961825A1 (en) | 2007-02-26 | 2008-08-27 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Method for predicting the occurrence of metastasis in breast cancer patients |
| CN101796072B (zh) | 2007-05-24 | 2014-09-24 | 埃博灵克斯股份有限公司 | 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽 |
| WO2008145125A1 (en) | 2007-05-31 | 2008-12-04 | Dako Denmark A/S | Methods for utilizing esr copy number changes in breast cancer treatments and prognoses |
| NZ562237A (en) * | 2007-10-05 | 2011-02-25 | Pacific Edge Biotechnology Ltd | Proliferation signature and prognosis for gastrointestinal cancer |
| WO2009049410A1 (en) | 2007-10-18 | 2009-04-23 | University Health Network | Clioquinol for the treatment of hematological malignancies |
| US20110130296A1 (en) | 2008-03-14 | 2011-06-02 | The Regents Of The University Of California | Multi-gene classifiers and prognostic indicators for cancers |
| CN102123708A (zh) | 2008-06-06 | 2011-07-13 | 大学健康网络 | 用于治疗恶性血液疾病的8-羟基喹啉衍生物 |
| US8728738B2 (en) | 2008-07-02 | 2014-05-20 | Assistance Publique-Hopitaux De Paris | Method for predicting clinical outcome of patients with non-small cell lung carcinoma |
| ES2338843B1 (es) | 2008-07-02 | 2011-01-24 | Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas | Huella genomica de cancer de mama. |
| US8642270B2 (en) | 2009-02-09 | 2014-02-04 | Vm Institute Of Research | Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer |
| SG10201507044PA (en) | 2009-05-29 | 2015-10-29 | Hoffmann La Roche | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| ES2546410T3 (es) | 2009-08-06 | 2015-09-23 | John Wayne Cancer Institute | Diagnosis de cáncer de mama, y otros tipos de cáncer, de tipo basal primario y metastásico |
| ES2562274T3 (es) | 2010-10-06 | 2016-03-03 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Procedimiento para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de mama |
| US20140162887A1 (en) | 2011-02-04 | 2014-06-12 | Bioarray Therapeutics, Inc. | Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment |
| AU2012229123B2 (en) | 2011-03-15 | 2017-02-02 | British Columbia Cancer Agency Branch | Methods of treating breast cancer with anthracycline therapy |
| EP2780469A1 (en) | 2011-11-18 | 2014-09-24 | Vanderbilt University | Markers of triple-negative breast cancer and uses thereof |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| ES2705237T3 (es) | 2012-06-06 | 2019-03-22 | Fundacio Inst De Recerca Biomedica Irb Barcelona | Método para el diagnóstico y el pronóstico de metástasis del cáncer de pulmón |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| DK2906718T3 (da) | 2012-10-12 | 2019-07-01 | Inbiomotion Sl | Fremgangsmåde til diagnose, prognose og behandling af prostatakræftmetastase under anvendelse af c-maf |
| AU2014229505B2 (en) | 2013-03-15 | 2020-02-27 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the prognosis and treatment of cancer metastasis |
| US20160032399A1 (en) | 2013-03-15 | 2016-02-04 | Inbiomotion S.L. | Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis |
| BR112015023510A2 (pt) | 2013-03-15 | 2017-10-10 | Fundacio Inst De Recerca Biomedica Irb Barcelona | método para o diagnóstico, prognóstico e tratamento de câncer metastático |
| JP6550045B2 (ja) | 2013-10-09 | 2019-07-24 | フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）Ｆｕｎｄａｃｉｏ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｒｅｃｅｒｃａ Ｂｉｏｍｅｄｉｃａ （Ｉｒｂ Ｂａｒｃｅｌｏｎａ） | 乳がんに由来する骨の転移がんの予後診断および処置のための方法 |
| JP2017538412A (ja) | 2014-12-11 | 2017-12-28 | インバイオモーション エセ．エレ． | ヒトｃ−ｍａｆに対する結合メンバー |
| CN117230193A (zh) | 2016-05-25 | 2023-12-15 | 生物运动有限公司 | 基于c-maf状态的乳腺癌治疗性治疗 |
| EP3713581A1 (en) | 2017-11-22 | 2020-09-30 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf |
-
2011
- 2011-10-05 ES ES11791605.6T patent/ES2562274T3/es active Active
- 2011-10-05 ES ES19159414T patent/ES2911505T3/es active Active
- 2011-10-05 CN CN201810147703.5A patent/CN108192972B/zh active Active
- 2011-10-05 JP JP2013532235A patent/JP6159254B2/ja active Active
- 2011-10-05 DK DK15180897.9T patent/DK3091085T3/da active
- 2011-10-05 WO PCT/ES2011/070693 patent/WO2012045905A2/es not_active Ceased
- 2011-10-05 EP EP19159414.2A patent/EP3517630B1/en active Active
- 2011-10-05 EP EP11791605.6A patent/EP2626431B1/en active Active
- 2011-10-05 MX MX2013003880A patent/MX344315B/es active IP Right Grant
- 2011-10-05 BR BR112013008505-3A patent/BR112013008505B1/pt active IP Right Grant
- 2011-10-05 MX MX2016016496A patent/MX382266B/es unknown
- 2011-10-05 AU AU2011311452A patent/AU2011311452B2/en active Active
- 2011-10-05 KR KR1020197001458A patent/KR102240323B1/ko active Active
- 2011-10-05 DK DK11791605.6T patent/DK2626431T3/en active
- 2011-10-05 KR KR1020137011176A patent/KR101944555B1/ko active Active
- 2011-10-05 EP EP15180897.9A patent/EP3091085B1/en active Active
- 2011-10-05 CA CA2813674A patent/CA2813674C/en active Active
- 2011-10-05 CN CN201180058347.6A patent/CN103339265B/zh active Active
- 2011-10-05 US US13/878,114 patent/US10047398B2/en active Active
- 2011-10-05 ES ES15180897T patent/ES2721639T3/es active Active
- 2011-10-11 AR ARP110103721A patent/AR083357A1/es unknown
-
2016
- 2016-11-30 AU AU2016266009A patent/AU2016266009B2/en active Active
-
2017
- 2017-01-26 JP JP2017011967A patent/JP6571698B2/ja active Active
-
2018
- 2018-03-22 JP JP2018054132A patent/JP2018099132A/ja active Pending
- 2018-07-06 US US16/028,530 patent/US11072831B2/en active Active
-
2019
- 2019-03-05 AU AU2019201493A patent/AU2019201493B2/en active Active
- 2019-08-08 JP JP2019146185A patent/JP6946385B2/ja active Active
-
2021
- 2021-06-02 AU AU2021203599A patent/AU2021203599B2/en active Active
- 2021-07-26 US US17/385,568 patent/US12312642B2/en active Active
- 2021-09-15 JP JP2021150170A patent/JP2021192636A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013541339A5 (enExample) | ||
| JP2015521050A5 (enExample) | ||
| JP2018078911A5 (enExample) | ||
| JP6781184B2 (ja) | がん転移の予後診断および処置のための方法 | |
| CN105324491B (zh) | 用于癌症转移的诊断和治疗的方法 | |
| JP2016105731A5 (enExample) | ||
| JP2016516403A5 (enExample) | ||
| WO2013182912A4 (en) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis | |
| CN105980576B (zh) | 用于源自乳腺癌的骨转移癌的预后和治疗的方法 | |
| JP6636067B2 (ja) | ｃ−ＭＡＦを用いた前立腺がん転移の診断、予後診断および処置のための方法 | |
| JP5690588B2 (ja) | 肝細胞癌のサブタイプを決定し、肝癌幹細胞を検出するための方法 | |
| CN103339265B (zh) | 用于乳腺癌转移的诊断、预后和治疗的方法 | |
| JP2019523641A5 (enExample) | ||
| JP2016539625A5 (enExample) | ||
| CN103608683A (zh) | Hedgehog抑制剂治疗的生物标志物 | |
| JP2012522756A5 (enExample) | ||
| JP2008536480A5 (enExample) | ||
| CN117230193A (zh) | 基于c-maf状态的乳腺癌治疗性治疗 | |
| JP6612232B2 (ja) | 対象のマルチキナーゼ阻害剤に対する応答性を予測する遺伝子発現シグネチャ、及びその使用 | |
| Puente et al. | Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma | |
| Reddi et al. | The putative PAX8/PPARγ fusion oncoprotein exhibits partial tumor suppressor activity through up-regulation of micro-RNA-122 and dominant-negative PPARγ activity | |
| US20210079476A1 (en) | Biomarkers of renal osteodystrophy type | |
| US20160258027A1 (en) | Ddx43 as a biomarker of resistance to mek1/2 inhibitors | |
| JP2010148501A (ja) | がんマーカー、及び、がんの治療剤 | |
| Shou | The prognostic value of PRL-3 overexpression in colon cancer and the molecular mechanism of PRL-3 promoting cancer cell metastasis |